➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Boehringer Ingelheim
Colorcon
AstraZeneca
Merck

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

Litigation Details for Shire Development, LLC v. Mylan Pharmaceuticals, Inc. (M.D. Fla. 2012)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in Shire Development, LLC v. Mylan Pharmaceuticals, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Free Forever Trial .

Details for Shire Development, LLC v. Mylan Pharmaceuticals, Inc. (M.D. Fla. 2012)

Date Filed Document No. Description Snippet Link To Document
2014-05-30 138 its Counterclaim as to invalidity of U.S. Patent No. 6,773,720 without prejudice by Mylan Pharmaceuticals…2012 11 August 2015 8:12-cv-01190 830 Patent None District Court, M.D. Florida External link to document
2015-02-05 221 a Hatch-Waxman patent infringement case7 involving United States Patent No. 6,773,720 and the branded…appeal of related case regarding same patent as to whether “patent exhaustion” doctrine barred claim…opinion in Shire v. Watson – regarding the very patent-in-suit in this case.3 The case was remanded …Circuit opinion. 7 The Hatch-Waxman Act governs patent lawsuits between innovator and generic pharmaceutical…multiple litigations at play regarding the same patent because multiple companies have attempted generic External link to document
2015-02-23 230 infringement of United States Patent No. 6,773,720 (the “#720 Patent”). Prior to bringing suit against…claim was sufficiently definite and held that the patent was therefore valid. See id. Upon appeal, the Federal… reversed, finding the claim indefinite and the patent invalid. See id. at 833. …district court reviews only evidence intrinsic to the patent . . . the judge’s determination will amount solely…claim, ordinary meaning of the claim terms, and patent’s description of the invention). The Federal External link to document
2015-03-23 233 This patent infringement case concerns United States Patent No. 6,773,720 (the “720 patent”), which…define the scope of the patented invention.”). “It is a ‘bedrock principle’ of patent law that ‘the claims…1989) (“A claim in a patent provides the metes and bounds of the right which the patent confers on the …dispersed” and “incorporated” in the ‘720 patent. See, e.g., ‘720 patent at 2:50-53. At bottom, there…pharmaceutical compositions.” ‘720 patent at claim 1. Second, the patent makes clear that any coatings are External link to document
2017-01-26 503 judgment of infringement of U.S. Patent No. 6,773,720 (the “’720 Patent”), entitled “Mesalazine controlled…colitis. 5. U.S. Patent No. 6,773,720 (“the ‘720 patent”), entitled “Mesalazine controlled…expiration of the '720 Patent will constitute an act of infringement of the '720 Patent by Mylan. 3. A judgment…of law on the issue of patent infringement.1 Shire filed this patent infringement case pursuant… States Patent and Trademark Office (“USPTO”) on August 10, 2004. Id. at ¶ 11. U.S. Patent Application External link to document
2013-12-30 63 upon Plaintiffs’ patent, specifically United States Patent No. 6,773,720 (the “Patent”). (Dkt. No. … the Patent and to present for deposition three of the four inventors listed on the Patent. (Dkt…56). Plaintiffs initiated this action for patent infringement under the Hatch-Waxman amendments …products infringed one or more claims of the Patent. Obviously, Plaintiffs have employed various discovery…deposition three of the four inventors listed on the Patent (Dkt. Nos. 43, 48)—a hearing is 4 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
Medtronic
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.